News

Workers at TÜV SÜD Nuclear Technologies have decided to support Muscular Dystrophy UK throughout 2019 in a bid to help beat muscle-wasting conditions.

Supporters who have pledged a Gift in their Will to Muscular Dystrophy UK were invited to visit the research lab at Royal Holloway University.

Spinraza – the first treatment for spinal muscular atrophy (SMA) – is due to be made available on the NHS in Scotland for children and adults with SMA Types 2 and 3.

We have heard today that, subject to sign-off, Spinraza will be available on the NHS in Scotland for children and adults with SMA Types 1, 2 and 3 from April 2019.

Solid Biosciences today announced preliminary findings from its IGNITE-DMD trial, which has so far tested SGT-001 in three boys.

A five year old Leicestershire boy who has muscular dystrophy will fire the gun to start the third Town and Gown 10k run

French pharmaceutical company Pharnext has announced that PXT3003 has been granted Fast Track Designation by the US Food and Drug Administration (FDA).

The continued delays in the assessment process for the spinal muscular atrophy (SMA) treatment Spinraza were highlighted by MPs in a House of Commons debate yesterday.

Researchers at Great Ormond Street Hospital (GOSH) are carrying out a research study to find out more about the emotion system of the brain in boys with Duchenne.

A new online course has launched for teaching and education staff working with secondary school children with a muscle-wasting condition.